Diagnosis and Treatment > Investigation > Molecular genetic analysis

You are looking at 41 - 50 of 69 items

N Chelaghma Department of Endocrinology, Peterborough City Hospital, Peterborough, UK

Search for other papers by N Chelaghma in
Google Scholar
PubMed
Close
,
J Rajkanna Department of Endocrinology, Peterborough City Hospital, Peterborough, UK

Search for other papers by J Rajkanna in
Google Scholar
PubMed
Close
,
J Trotman East Midlands and East of England NHS Genomic Laboratory Hub, Cambridge University Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK

Search for other papers by J Trotman in
Google Scholar
PubMed
Close
,
G Fuller East Midlands and East of England NHS Genomic Laboratory Hub, Cambridge University Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK

Search for other papers by G Fuller in
Google Scholar
PubMed
Close
,
T Elsey East Midlands and East of England NHS Genomic Laboratory Hub, Cambridge University Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK

Search for other papers by T Elsey in
Google Scholar
PubMed
Close
,
SM Park Department of Clinical Genetics, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK

Search for other papers by SM Park in
Google Scholar
PubMed
Close
, and
SO Oyibo Department of Endocrinology, Peterborough City Hospital, Peterborough, UK

Search for other papers by SO Oyibo in
Google Scholar
PubMed
Close

Summary

Hypogonadotrophic hypogonadism is due to impaired or reduced gonadotrophin secretion from the pituitary gland. In the absence of any anatomical or functional lesions of the pituitary or hypothalamic gland, the hypogonadotrophic hypogonadism is referred to as idiopathic hypogonadotrophic hypogonadism (IHH). We present a case of a young lady born to consanguineous parents who was found to have IHH due to a rare gene mutation.

Learning points:

  • The genetic basis of a majority of cases of IHH remains unknown.

  • IHH can have different clinical endocrine manifestations.

  • Patients can present late to the healthcare service because of unawareness and stigmata associated with the clinical features.

  • Family members of affected individuals can be affected to varying degrees.

Open access
Jia Xuan Siew Paediatric Medicine, KK Women’s and Children’s Hospital, Singapore, Singapore

Search for other papers by Jia Xuan Siew in
Google Scholar
PubMed
Close
and
Fabian Yap Paediatric Endocrinology, KK Women’s and Children’s Hospital, Singapore, Singapore

Search for other papers by Fabian Yap in
Google Scholar
PubMed
Close

Summary

Growth anomaly is a prominent feature in Wolf-Hirschhorn syndrome (WHS), a rare congenital disorder caused by variable deletion of chromosome 4p. While growth charts have been developed for WHS patients 0–4 years of age and growth data available for Japanese WHS patients 0–17 years, information on pubertal growth and final height among WHS children remain lacking. Growth hormone (GH) therapy has been reported in two GH-sufficient children with WHS, allowing for pre-puberty catch up growth; however, pubertal growth and final height information was also unavailable. We describe the complete growth journey of a GH-sufficient girl with WHS from birth until final height (FH), in relation to her mid parental height (MPH) and target range (TR). Her growth trajectory and pubertal changes during childhood, when she was treated with growth hormone (GH) from 3 years 8 months old till 6 months post-menarche at age 11 years was fully detailed.

Learning points:

  • Pubertal growth characteristics and FH information in WHS is lacking.

  • While pre-pubertal growth may be improved by GH, GH therapy may not translate to improvement in FH in WHS patients.

  • Longitudinal growth, puberty and FH data of more WHS patients may improve the understanding of growth in its various phases (infancy/childhood/puberty).

Open access
Akihiko Ando Division of Endocrinology and Metabolism, Department of Internal Medicine, Jichi Medical University, Tochigi, Japan

Search for other papers by Akihiko Ando in
Google Scholar
PubMed
Close
,
Shoichiro Nagasaka Division of Endocrinology and Metabolism, Department of Internal Medicine, Jichi Medical University, Tochigi, Japan
Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Kanagawa Japan

Search for other papers by Shoichiro Nagasaka in
Google Scholar
PubMed
Close
, and
Shun Ishibashi Division of Endocrinology and Metabolism, Department of Internal Medicine, Jichi Medical University, Tochigi, Japan

Search for other papers by Shun Ishibashi in
Google Scholar
PubMed
Close

Summary

We report a case of a woman with diabetes mellitus caused by a genetic defect in ABCC8-coding sulfonylurea receptor 1 (SUR1), a subunit of the ATP-sensitive potassium (KATP) channel protein. She was diagnosed with diabetes at 7 days after birth. After intravenous insulin drip for 1 month, her hyperglycaemia remitted. At the age of 13 years, her diabetes relapsed, and after that she had been treated by intensive insulin therapy for 25 years with relatively poor glycaemic control. She was switched to oral sulfonylurea therapy and attained euglycaemia. In addition, her insulin secretory capacity was ameliorated gradually.

Learning points:

  • Genetic testing should be considered in any individuals or family with diabetes that occurred within the first year or so of life.

  • Sulfonylurea can achieve good glycaemic control in patients with KATP channel mutations by restoring endogenous insulin secretion, even if they were treated with insulin for decades.

  • Early screening and genetic testing are important to improve the prognosis of patients with neonatal diabetes mellitus arising from ABCC8 or KCNJ11 mutation.

Open access
Catherine Alguire Division of Endocrinology, Department of Medicine and Research Center (CRCHUM), Centre hospitalier de l’Université de Montréal, Montreal, Québec, Canada

Search for other papers by Catherine Alguire in
Google Scholar
PubMed
Close
,
Jessica Chbat Division of Endocrinology, Department of Medicine and Research Center (CRCHUM), Centre hospitalier de l’Université de Montréal, Montreal, Québec, Canada

Search for other papers by Jessica Chbat in
Google Scholar
PubMed
Close
,
Isabelle Forest Department of Psychiatry, Centre hospitalier Pierre-Le Gardeur, Terrebonne, Québec, Canada

Search for other papers by Isabelle Forest in
Google Scholar
PubMed
Close
,
Ariane Godbout Division of Endocrinology, Department of Medicine and Research Center (CRCHUM), Centre hospitalier de l’Université de Montréal, Montreal, Québec, Canada

Search for other papers by Ariane Godbout in
Google Scholar
PubMed
Close
, and
Isabelle Bourdeau Division of Endocrinology, Department of Medicine and Research Center (CRCHUM), Centre hospitalier de l’Université de Montréal, Montreal, Québec, Canada

Search for other papers by Isabelle Bourdeau in
Google Scholar
PubMed
Close

Summary

Pheochromocytoma is a rare tumor of the adrenal gland. It often presents with the classic triad of headache, palpitations and generalized sweating. Although not described as a typical symptom of pheochromocytoma, anxiety is the fourth most common symptom reported by patients suffering of pheochromocytoma. We report the case of a 64 year old man who had severe anxiety and panic disorder as presenting symptoms of pheochromocytoma. After 13 years of psychiatric follow-up, the patient was diagnosed with malignant pheochromocytoma. After surgical resection of his pheochromocytoma and his hepatic metastases, the major panic attacks completely disappeared, the anxiety symptoms improved significantly and the psychiatric medications were stopped except for a very low maintenance dose of venlafaxine. We found in our cohort of 160 patients with pheochromocytoma 2 others cases of apparently benign tumors with severe anxiety that resolved after pheochromocytoma resection. These cases highlight that pheochromocytoma should be included in the differential diagnosis of refractory anxiety disorder.

Learning points:

  • Anxiety and panic disorder may be the main presenting symptoms of pheochromocytoma.

  • The diagnosis of pheochromocytoma should be excluded in cases of long-term panic disorder refractory to medications since the anxiety may be secondary to a catecholamine-secreting tumor.

  • Surgical treatment of pheochromocytoma leads to significant improvement of anxiety disorders.

Open access
C E Stiles Department of Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London, UK

Search for other papers by C E Stiles in
Google Scholar
PubMed
Close
,
R Thuraisingham Department of Nephrology, Barts Health NHS Trust, London, UK

Search for other papers by R Thuraisingham in
Google Scholar
PubMed
Close
,
D Bockenhauer UCL centre for Nephrology and Great Ormond Street Hospital NHS Trust, London, UK

Search for other papers by D Bockenhauer in
Google Scholar
PubMed
Close
,
L Platts North East Thames Regional Genetics Laboratory, Great Ormond Street Hospital NHS Trust, London, UK

Search for other papers by L Platts in
Google Scholar
PubMed
Close
,
A V Kumar North East Thames Regional Genetics Service, Great Ormond Street Hospital NHS Trust, London, UK

Search for other papers by A V Kumar in
Google Scholar
PubMed
Close
, and
M Korbonits Department of Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London, UK

Search for other papers by M Korbonits in
Google Scholar
PubMed
Close

Summary

29-year-old female presenting with an 8-year history of unexplained hypomagnesaemia, which was severe enough to warrant intermittent inpatient admission for intravenous magnesium. Urinary magnesium was inappropriately normal in the context of hypomagnesaemia indicating magnesium wasting. Ultrasound imaging demonstrated unilateral renal cysts and computed tomography of kidneys, ureters and bladder showed a bicornuate uterus. Referral to genetic services and subsequent testing revealed a de novo HNF1B deletion.

Learning points:

  • HNF1B loss-of-function mutations are one of the most common monogenic causes of congenital anomalies of the kidney and urinary tract.

  • Those with HNF1B mutations may have some of a constellation of features (renal and hepatic cysts, deranged liver function tests, maturity onset diabetes of the young type 5 (MODY5), bicornuate uterus, hyperparathyroidism, hyperuricaemic gout, but presenting features are highly heterogeneous amongst patients and no genotype/phenotype correlation exists.

  • HNF1B mutations are inherited in an autosomal dominant pattern but up to 50% of cases are de novo.

  • HNF1B mutations can be part of the Chr17q12 deletion syndrome, a contiguous gene deletion syndrome.

  • Inorganic oral magnesium replacements are generally poorly tolerated with side effects of diarrhoea. Organic magnesium compounds, such as magnesium aspartate, are better absorbed oral replacement therapies.

Open access
Lukas Burget Division of Endocrinology and Diabetes, Cantonal Hospital Lucerne, Lucerne, Switzerland

Search for other papers by Lukas Burget in
Google Scholar
PubMed
Close
,
Laura Audí Parera Pediatric Endocrinology Research Unit, Vall d`Hebron, Institut de Recerca, CIBERER, Instituto de Salud Carlos III, Barcelona, Spain

Search for other papers by Laura Audí Parera in
Google Scholar
PubMed
Close
,
Monica Fernandez-Cancio Pediatric Endocrinology Research Unit, Vall d`Hebron, Institut de Recerca, CIBERER, Instituto de Salud Carlos III, Barcelona, Spain

Search for other papers by Monica Fernandez-Cancio in
Google Scholar
PubMed
Close
,
Rolf Gräni Division of Endocrinology and Diabetes, Cantonal Hospital Lucerne, Lucerne, Switzerland

Search for other papers by Rolf Gräni in
Google Scholar
PubMed
Close
,
Christoph Henzen Division of Endocrinology and Diabetes, Cantonal Hospital Lucerne, Lucerne, Switzerland

Search for other papers by Christoph Henzen in
Google Scholar
PubMed
Close
, and
Christa E Flück Pediatric Endocrinology, Diabetology and Metabolism, Bern University Children’s Hospital and Department of BioMedical Research, University of Bern, Bern, Switzerland

Search for other papers by Christa E Flück in
Google Scholar
PubMed
Close

Summary

Steroidogenic acute regulatory protein (STAR) is a key protein for the intracellular transport of cholesterol to the mitochondrium in endocrine organs (e.g. adrenal gland, ovaries, testes) and essential for the synthesis of all steroid hormones. Several mutations have been described and the clinical phenotype varies strongly and may be grouped into classic lipoid congenital adrenal hyperplasia (LCAH), in which all steroidogenesis is disrupted, and non-classic LCAH, which resembles familial glucocorticoid deficiency (FGD), which affects predominantly adrenal functions. Classic LCAH is characterized by early and potentially life-threatening manifestation of primary adrenal insufficiency (PAI) with electrolyte disturbances and 46,XY disorder of sex development (DSD) in males as well as lack of pubertal development in both sexes. Non-classic LCAH manifests usually later in life with PAI. Nevertheless, life-long follow-up of gonadal function is warranted. We describe a 26-year-old female patient who was diagnosed with PAI early in life without detailed diagnostic work-up. At the age of 14 months, she presented with hyperpigmentation, elevated ACTH and low cortisol levels. As her older brother was diagnosed with PAI two years earlier, she was put on hydrocortisone and fludrocortisone replacement therapy before an Addisonian crisis occurred. Upon review of her case in adulthood, consanguinity was noted in the family. Genetic analysis for PAI revealed a homozygous mutation in the STAR gene (c.562C>T, p.Arg188Cys) in both siblings. This mutation has been previously described in non-classic LCAH. This case illustrates that early onset, familial PAI is likely due to autosomal recessive genetic mutations in known genes causing PAI.

Learning points:

  • In childhood-onset PAI, a genetic cause is most likely, especially in families with consanguinity.

  • Adult patients with an etiologically unsolved PAI should be reviewed repeatedly and genetic work-up should be considered.

  • Knowing the exact genetic diagnosis in PAI is essential for genetic counselling and may allow disease-specific treatment.

  • Young men and women with NCLAH due to homozygous STAR Arg188Cys mutation should be investigated for their gonadal function as hypogonadism and infertility might occur during puberty or in early adulthood.

Open access
Caroline Bachmeier Endocrinology Department, Townsville Hospital, Townsville, Queensland, Australia

Search for other papers by Caroline Bachmeier in
Google Scholar
PubMed
Close
,
Chirag Patel Genetic Health Queensland, Royal Brisbane and Women’s Hospital, Herston, Queensland, Australia

Search for other papers by Chirag Patel in
Google Scholar
PubMed
Close
,
Peter Kanowski Clinical Pathology/Histopathology, Sullivan Nicolaides Pathology, Townsville, Queensland, Australia

Search for other papers by Peter Kanowski in
Google Scholar
PubMed
Close
, and
Kunwarjit Sangla Endocrinology Department, Townsville Hospital, Townsville, Queensland, Australia
James Cook University, Townsville, Queensland, Australia

Search for other papers by Kunwarjit Sangla in
Google Scholar
PubMed
Close

Summary

Primary hyperparathyroidism (PH) is a common endocrine abnormality and may occur as part of a genetic syndrome. Inactivating mutations of the tumour suppressor gene CDC73 have been identified as accounting for a large percentage of hyperparathyroidism-jaw tumour syndrome (HPT-JT) cases and to a lesser degree account for familial isolated hyperparathyroidism (FIHP) cases. Reports of CDC73 whole gene deletions are exceedingly rare. We report the case of a 39 year-old woman with PH secondary to a parathyroid adenoma associated with a large chromosomal deletion (2.5 Mb) encompassing the entire CDC73 gene detected years after parathyroidectomy. This case highlights the necessity to screen young patients with hyperparathyroidism for an underlying genetic aetiology. It also demonstrates that molecular testing for this disorder should contain techniques that can detect large deletions.

Learning points:

  • Necessity of genetic screening for young people with hyperparathyroidism.

  • Importance of screening for large, including whole gene CDC73 deletions.

  • Surveillance for patients with CDC73 gene mutations includes regular calcium and parathyroid hormone levels, dental assessments and imaging for uterine and renal tumours.

Open access
Jennifer Hague Departments of Clinical Genetics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

Search for other papers by Jennifer Hague in
Google Scholar
PubMed
Close
,
Ruth Casey Departments of Diabetes and Endocrinology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
Department of Medical Genetics, University of Cambridge and NIHR Cambridge Biomedical Research Centre and Cancer Research UK Cambridge Centre, Cambridge, UK

Search for other papers by Ruth Casey in
Google Scholar
PubMed
Close
,
Jonathan Bruty Departments of Clinical Genetics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

Search for other papers by Jonathan Bruty in
Google Scholar
PubMed
Close
,
Tom Legerton Departments of Clinical Genetics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

Search for other papers by Tom Legerton in
Google Scholar
PubMed
Close
,
Stephen Abbs Departments of Clinical Genetics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

Search for other papers by Stephen Abbs in
Google Scholar
PubMed
Close
,
Susan Oddy Department of Clinical Biochemistry, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

Search for other papers by Susan Oddy in
Google Scholar
PubMed
Close
,
Andrew S Powlson Departments of Diabetes and Endocrinology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

Search for other papers by Andrew S Powlson in
Google Scholar
PubMed
Close
,
Mohamed Majeed Departments of Diabetes and Endocrinology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

Search for other papers by Mohamed Majeed in
Google Scholar
PubMed
Close
,
Mark Gurnell Departments of Diabetes and Endocrinology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

Search for other papers by Mark Gurnell in
Google Scholar
PubMed
Close
,
Soo-Mi Park Departments of Clinical Genetics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

Search for other papers by Soo-Mi Park in
Google Scholar
PubMed
Close
, and
Helen Simpson Department of Diabetes and Endocrinology, UCLH NHS Foundation Trust, London, UK

Search for other papers by Helen Simpson in
Google Scholar
PubMed
Close

Summary

Activating mutations in AVPR2 are associated with nephrogenic syndrome of inappropriate antidiuresis (NSIAD). NSIAD causes hyponatremia, decreased serum osmolality and clinical symptoms, which may present from birth or in infancy and include hypotonia, irritability, vomiting and/or seizures. Symptoms in later life are often less specific and include malaise, dizziness, confusion, tiredness and headache. NSIAD is a rare X-linked condition, which is associated with a variable phenotype in males, of whom some present in infancy but others do not become symptomatic until adulthood, or occasionally, never. Female carriers may present with episodes of hyponatremia, usually found incidentally. Literature in this field is limited; namely, two clinical reports describing a female proband, both diagnosed in infancy. We describe, for the first time, the case of an adult female proband with NSIAD, who had longstanding associated symptoms of tiredness, headache, temporary memory loss and mood changes as well as hyponatremia and decreased serum osmolality. A water load test demonstrated an inability to dilute urine and gene sequencing confirmed a recurrent activating mutation in AVPR2. The variant was inherited from the proband’s mother who had had longstanding episodes of transient asymptomatic hyponatremia. This is the third report of a female proband with NSIAD and is the first female reported who sought medical treatment for chronic symptoms from adulthood. This case acts as a reminder of the importance of considering NSIAD as a diagnosis in females of all ages with unexplained hyponatremia.

Learning points:

  • Activating mutations in the AVPR2 gene are associated with the rare X-linked condition nephrogenic syndrome of inappropriate antidiuresis.

  • NSIAD is associated with hyponatremia, decreased serum osmolality and inappropriately increased urinary osmolality. Early clinical symptoms in infancy include hypotonia, irritability, vomiting and/or seizures. Symptoms in later life include malaise, dizziness, confusion, tiredness and headache.

  • NSIAD should be considered in female, as well as male, patients who present with unexplained hyponatremia and decreased serum osmolality. Family history may reveal relevant symptoms or biochemical features in other family members. However, family history may not always be informative due to the variable nature of the condition or if the proband has a de novo pathogenic variant.

  • A water load test with measurement of AVP may be informative in distinguishing NSIAD from SIADH. Measurement of co-peptin levels may be considered, in substitution for direct measurement of AVP.

  • Patients with NSIAD should be counseled about appropriate daily fluid volume intake. Potential episodes of fluid overload should be avoided.

Open access
Syed Ali Imran Division of Endocrinology and Metabolism, Dalhousie University, Halifax, Nova Scotia, Canada

Search for other papers by Syed Ali Imran in
Google Scholar
PubMed
Close
,
Khaled A Aldahmani Division of Endocrinology, Tawam Hospial, Al-Ain, UAE

Search for other papers by Khaled A Aldahmani in
Google Scholar
PubMed
Close
,
Lynette Penney Department of Pediatrics, Tawam Hospial, Al-Ain, UAE

Search for other papers by Lynette Penney in
Google Scholar
PubMed
Close
,
Sidney E Croul Department of Pathology, Tawam Hospial, Al-Ain, UAE

Search for other papers by Sidney E Croul in
Google Scholar
PubMed
Close
,
David B Clarke Department of Neurosurgery, Dalhousie University, Halifax, Nova Scotia, Canada

Search for other papers by David B Clarke in
Google Scholar
PubMed
Close
,
David M Collier Centre for Endocrinology, Barts and the London School of Medicine, Queen Mary University of London, London, UK

Search for other papers by David M Collier in
Google Scholar
PubMed
Close
,
Donato Iacovazzo Centre for Endocrinology, Barts and the London School of Medicine, Queen Mary University of London, London, UK

Search for other papers by Donato Iacovazzo in
Google Scholar
PubMed
Close
, and
Márta Korbonits Centre for Endocrinology, Barts and the London School of Medicine, Queen Mary University of London, London, UK

Search for other papers by Márta Korbonits in
Google Scholar
PubMed
Close

Summary

Early-onset acromegaly causing gigantism is often associated with aryl-hydrocarbon-interacting receptor protein (AIP) mutation, especially if there is a positive family history. A15y male presented with tiredness and visual problems. He was 201 cm tall with a span of 217 cm. He had typical facial features of acromegaly, elevated IGF-1, secondary hypogonadism and a large macroadenoma. His paternal aunt had a history of acromegaly presenting at the age of 35 years. Following transsphenoidal surgery, his IGF-1 normalized and clinical symptoms improved. He was found to have a novel AIP mutation destroying the stop codon c.991T>C; p.*331R. Unexpectedly, his father and paternal aunt were negative for this mutation while his mother and older sister were unaffected carriers, suggesting that his aunt represents a phenocopy.

Learning points:

  • Typical presentation for a patient with AIP mutation with excess growth and eunuchoid proportions.

  • Unusual, previously not described AIP variant with loss of the stop codon.

  • Phenocopy may occur in families with a disease-causing germline mutation.

Open access
Ken Takeshima First Department of Internal Medicine, Wakayama Medical University, Wakayama,, Japan

Search for other papers by Ken Takeshima in
Google Scholar
PubMed
Close
,
Hiroyuki Ariyasu First Department of Internal Medicine, Wakayama Medical University, Wakayama,, Japan

Search for other papers by Hiroyuki Ariyasu in
Google Scholar
PubMed
Close
,
Tatsuya Ishibashi First Department of Internal Medicine, Wakayama Medical University, Wakayama,, Japan

Search for other papers by Tatsuya Ishibashi in
Google Scholar
PubMed
Close
,
Shintaro Kawai First Department of Internal Medicine, Wakayama Medical University, Wakayama,, Japan

Search for other papers by Shintaro Kawai in
Google Scholar
PubMed
Close
,
Shinsuke Uraki First Department of Internal Medicine, Wakayama Medical University, Wakayama,, Japan

Search for other papers by Shinsuke Uraki in
Google Scholar
PubMed
Close
,
Jinsoo Koh Department of Neurology, Wakayama Medical University, Wakayama,, Japan

Search for other papers by Jinsoo Koh in
Google Scholar
PubMed
Close
,
Hidefumi Ito Department of Neurology, Wakayama Medical University, Wakayama,, Japan

Search for other papers by Hidefumi Ito in
Google Scholar
PubMed
Close
, and
Takashi Akamizu First Department of Internal Medicine, Wakayama Medical University, Wakayama,, Japan

Search for other papers by Takashi Akamizu in
Google Scholar
PubMed
Close

Summary

Myotonic dystrophy type 1 (DM1) is an autosomal dominant multisystem disease affecting muscles, the eyes and the endocrine organs. Diabetes mellitus and primary hypogonadism are endocrine manifestations typically seen in patients with DM1. Abnormalities of hypothalamic–pituitary–adrenal (HPA) axis have also been reported in some DM1 patients. We present a case of DM1 with a rare combination of multiple endocrinopathies; diabetes mellitus, a combined form of primary and secondary hypogonadism, and dysfunction of the HPA axis. In the present case, diabetes mellitus was characterized by severe insulin resistance with hyperinsulinemia. Glycemic control improved after modification of insulin sensitizers, such as metformin and pioglitazone. Hypogonadism was treated with testosterone replacement therapy. Notably, body composition analysis revealed increase in muscle mass and decrease in fat mass in our patient. This implies that manifestations of hypogonadism could be hidden by symptoms of myotonic dystrophy. Our patient had no symptoms associated with adrenal deficiency, so adrenal dysfunction was carefully followed up without hydrocortisone replacement therapy. In this report, we highlight the necessity for evaluation and treatment of multiple endocrinopathies in patients with DM1.

Learning points:

  • DM1 patients could be affected by a variety of multiple endocrinopathies.

  • Our patients with DM1 presented rare combinations of multiple endocrinopathies; diabetes mellitus, combined form of primary and secondary hypogonadism and dysfunction of HPA axis.

  • Testosterone treatment of hypogonadism in patients with DM1 could improve body composition.

  • The patients with DM1 should be assessed endocrine functions and treated depending on the degree of each endocrine dysfunction.

Open access